Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/1b study of CPI-818 in patients with several types of T-cell lymphomas, including peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) in patients with several types of T-cell lymphomas, including peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and others

Trial Profile

A phase 1/1b study of CPI-818 in patients with several types of T-cell lymphomas, including peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) in patients with several types of T-cell lymphomas, including peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and others

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs CPI-818 (Primary)
  • Indications Cancer; Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Feb 2019 According to a Corvus Pharmaceuticals media release, company plans to initiate this study during the first quarter of 2019.
    • 10 Jan 2019 According to a Corvus Pharmaceuticals media release, company plans to submit an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in early 2019.
    • 19 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top